September 20, 2021


News Release 

September 20, 2021 


September 20, 2021, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7) (the  “Company” or “Gemina”) is pleased to provide an update on its current activities related to the  development of its first rapid diagnostic test targeting the SARS CoV-2 antigen, using the Company’s  patented breakthrough chemistry. The results represent a significant milestone on the path to  manufacturing Gemina’s first diagnostic test and demonstrates the power of Gemina’s chemistry in its  ability to effectively test at lower limits of detection when manufactured at scale. This confirmation allows  the company to begin exploring initial out-licensing opportunities.  

Understanding the Phase 1 Results 

Gemina products are built around our proprietary transformative chemistry platform that the Company  believes significantly improves the performance, limit of detection and production of biosensors for a  range of established and emergent diagnostic platforms, including rapid COVID-19 testing.  

With respect to Gemina’s initial product development program – a COVID-19 rapid diagnostic test, Gemina achieved prototype design freeze at the end of June 2021 and transferred the program to  International Point of Care (“IPOC”) for Phase 1 manufacturability testing. IPOC is a leading Canadian  company that develops, manufactures and supplies unique biological reagents, raw materials, and lateral  flow components for the in-vitro diagnostic industry and the research and development community.  

Phase 1 results indicate that IPOC was able to repeatedly detect 1 ng/mL of SARS-CoV-2 N protein in  pooled human saliva. This result confirms earlier independent laboratory results with Gemina’s prototype  SARS-CoV-2 rapid antigen test indicating the company was able to reliably detect recombinant SARS-CoV 2 nucleocapsid in saliva and nasal fluid samples with significantly higher sensitivity when compared with  a panel of seven leading commercial rapid antigen tests (Lancet – Corman, et al. 2021). The low Level of  Detection achieved in this test is five times better that the market leading tests evaluated in the Lancet  study. 

In the context of testing for viruses (like COVID-19), lower limit of detection will allow for earlier and more  reliable detection of the virus in patient samples. Since airborne transmission plays a critical role in the  distribution of the COVID-19 virus, having access to early, reliable and cost-effective detection plays a  critical role as a public health measure to control or limit the chains of infection, and prevent or reduce  viral spread. 

The positive data resulting from the Phase 1 assessment allows Gemina to move into Phases 2 and 3 of  the manufacturing trials at IPOC, which will subject the test to bench studies, including usability studies,  cross-reactivity studies, and clinical trials with North American and European Health Agencies. Importantly  for Gemina, the Phase 1 results and subsequent data from Phases 2 and 3 will also be used to initiate  licensing negotiations with established international diagnostic test providers. 

Following the saliva results, performance assessment in nasal fluid samples with both recombinant  nucleocapsid antigen and with inactivated virus are now underway at IPOC with results expected in late  Q3, 2021. 

“This is a major milestone in our journey towards manufacturing our first biosensor built on our disruptive  chemistry platform.” commented Rob Greene, founder and CTO of Gemina Labs. “Achievement of the 1  ng/mL limit of detection in a manufacturing setting is a strong result that allows us to move into Phase 2  with great confidence in the high performance of the test design.” 

CEO John Davies added “It is becoming increasingly clear that despite the positive impact of large-scale  vaccination programs, COVID cases continue to be a serious societal challenge. With new waves of the  pandemic there is a clear demand for widespread, low cost, rapid population testing and screening as an  essential public health measure. For regions of the developing world with low vaccination rates and  lacking the infrastructure for molecular testing, low-cost rapid testing may be the principal public health  measure. We believe Gemina Labs can make a major contribution to addressing this challenge at an  international level.” 

The Company is not making any express or implied claims that its product has the ability to eliminate, cure  or contain the COVID-19 virus. The Company will be seeking regulatory approval for our product(s) before  sales and clinical use are permitted.  

On Behalf of the Board of Directors 

John Davies 


Gemina Laboratories Ltd. 

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary  chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and  easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19,  influenza and other viruses. Additional information on the Company can be found at 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined  in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy  of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are not  limited to, information and statements regarding or inferring the future business, operations, financial  performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company.  Such statements include statements regarding the anticipated terms of any proposed transaction or  engagement. Information and statements which are not purely historical fact are forward-looking 

statements. Forward-looking information and statements involve and are subject to assumptions and  known and unknown risks, uncertainties, and other factors which may cause actual events, results,  performance, or achievements of the Company to be materially different from future events, results,  performance, and achievements expressed or implied by forward-looking information and statements  herein. Although the Company believes that any forward-looking information and statements herein are  reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such  information and statements, there can be no assurance that any such forward-looking information and  statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation  of such risks and uncertainties and should not place undue reliance upon such forward-looking  information and statements. Furthermore, the Company is presently unable to fully quantify the impact  that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may  affect planned or assumed performance moving forward. As such, any forward-looking information and  statements herein are made as of the date hereof, and except as required by applicable laws, the  Company assumes no obligation and disclaims any intention to update or revise any forward-looking  information and statements herein or to update the reasons that actual events or results could or do differ  from those projected in any forward looking information and statements herein, whether as a result of  new information, future events or results, or otherwise, except as required by applicable laws.  

For more information regrading the Company, please contact: 

James Tansey 

Telephone: 604-562-4546  


Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Press and Updates


December 20, 2022
Read More


December 20, 2022
Read More


December 19, 2022
Read More

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.